Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Burkitt Lymphoma 8Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Neoplasm, Residual 1Leukemia 1

Interventions

Rituximab 45Cyclophosphamide 34Doxorubicin 16fludarabine 14Prednisone 14Vincristine 13Etoposide 13ibrutinib 10Mycophenolic Acid 8Bortezomib 8Magnetic Resonance Spectroscopy 7Lenalidomide 7Cytarabine 7pembrolizumab 6Immunotherapy, Adoptive 6polatuzumab vedotin 5fludarabine phosphate 5Whole-Body Irradiation 5Vorinostat 5Tacrolimus 5Specimen Handling 5CT-P10 5obinutuzumab 4ibritumomab tiuxetan 4Nivolumab 4Ifosfamide 4Carmustine 4Carboplatin 4Antilymphocyte Serum 4tafasitamab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, B-Cell × tisagenlecleucel × Clear all
NCT04234061 2024-11-07

TARMAC

Peter MacCallum Cancer Centre, Australia

Phase 2 Active not recruiting
20 enrolled
Lymphoid

Lymphoma, B-Cell

NCT03610724 2024-06-20

BIANCA

Novartis

Phase 2 Completed
34 enrolled 19 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡